Trial Profile
Liposomal iRInotecan, Carboplatin or oXaliplatin in the First Line Treatment of Esophagogastric Cancer: a Randomized Phase 2 Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Capecitabine (Primary) ; Carboplatin (Primary) ; Fluorouracil (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Folinic acid
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LyRICX
- 12 Sep 2023 Planned number of patients changed from 310 to 320.
- 15 Dec 2022 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 15 Dec 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2024.